<DOC>
	<DOCNO>NCT00488995</DOCNO>
	<brief_summary>The purpose study determine CP-675,206 , monoclonal antibody CTLA4 , safe well-tolerated , reduce viral load , improve immune function patient infected HIV .</brief_summary>
	<brief_title>Safety And Efficacy Study Of CP-675,206 In HIV-Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>HIV infect man woman least 18 year age available follow period least 3 month Has stable antiretroviral regimen ≥3 month willing remain current antiretroviral regimen additional 3 month antiretroviral therapy least 8 week willing remain antiretroviral therapy another 3 month Plasma HIV 1 RNA ≥5,000 copies/mL measure Roche Amplicor HIV 1 Monitor screen visit CD4 Tcells ≥200 cells/mm3 History , significant evidence risk , chronic inflammatory autoimmunedisease ( eg , Addison 's disease , asthma , celiac disease , multiple sclerosis , Graves disease , Hashimoto 's thyroiditis , inflammatory bowel disease , psoriasis , rheumatoid arthritis , systemic lupus erythematosus , etc ) History inflammatory bowel disease ( eg , Crohn 's disease ulcerative colitis ) , celiac disease , chronic gastrointestinal condition associate diarrhea , current acute colitis origin , history diverticulitis ( even single episode ) evidence diverticulitis baseline , include evidence limit CTscan Exposure within previous 3 month drug know immunomodulatory effect ( eg , IL 2 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>HIV Therapeutic Vaccine</keyword>
</DOC>